logo-loader
viewSummit Therapeutics PLC

Summit Therapeutics 'taking leadership role' in development of new antibiotics

Summit Therapeutics PLC's (LON:SUMM) Dr Richard Pye speaks to Proactive London's Andrew Scott following a first quarter update on operational progress across the portfolio.

Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which can cause diarrhoea, SMT-571 for Gonorrhoea and DDS-04 which is aiming to treat Enterobacteriaceae, a family of bacteria that includes salmonella.

Quick facts: Summit Therapeutics PLC

Price: 23.75 GBX

AIM:SUMM
Market: AIM
Market Cap: £38.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics CEO says anti microbial resistance will be as big a...

Summit Therapeutics PLC (LON:SUMM) CEO Glyn Edwards sat down with Proactive at the 2019 BIO Investor Forum where is explained anti microbial resistance will be as big a problem as climate change. Edwards says recently, Summit reported that Phase II trials showed that antibiotic Ridinilazole...

2 weeks, 4 days ago

2 min read